Hematologic malignancies: An opportunity for targeted drug therapy

Oncologist

Volumn 6, Issue SUPPL. 5, 2001, Pages 1-3

  Gabrilove, J L ^a  

^a Derald H Ruttenberg Cancer Center   (United States)

Author keywords

Angiogenesis; Cancer; Chemotherapy; Leukemia; Myelodysplastic syndromes; Thrombocytopenia

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN;

BLOOD DISEASE; CANCER THERAPY; CONFERENCE PAPER; CYTOTOXICITY; ENZYME ACTIVATION; HEMATOPOIETIC STEM CELL; PANCYTOPENIA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0035158251     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-suppl_5-1     Document Type: Conference Paper

References (18)

1. The hallmarks of cancer
2. Oncogenic kinase signalling
3. Signaling - 2000 And beyond
4. Molecular genetics in acute leukemia
5. Principles of cancer management: Chemotherapy
6. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
7. Differentiation-inducing agents in the treatment of myelodysplastic syndromes
8. DNA methylation
9. Targeting hypomethylation of DNA to achieve cellular differentiation in MDS
10. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
11. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies
12. The vascular endothelial growth factor (VEGF) signaling pathway: A therapeutic target in patients with hematologic malignancies
13. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine
14. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1
15. The rationale and future potential of angiogenesis inhibitors in neoplasia
16. Clinical strategy for the development of angiogenesis inhibitors
17. The thrombocytopenia of cancer. Prospects for effective cytokine therapy
18. Targeted approaches for the treatment of thrombocytopenia